Headwinds

In its fourth-quarter earnings investor presentation, Johnson & Johnson (JNJ) highlighted increasing biosimilar and generic competition, pricing pressure, and the strengthening of the US dollar as key challenges for the company in fiscal 2019.

Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019Tailwinds

According to Johnson & Johnson’s fourth-quarter earnings conference call, the company has a strong core business with 26 products and platforms that generate revenues of $1.0 billion or more annually. This coupled with improved execution and new product launches across all of its business segments could drive Johnson & Johnson’s growth in fiscal 2019.

The company expects its Consumer business to grow at an above-market rate in 2019, driven by new product launches and improved go-to-market models. According to Johnson & Johnson’s fourth-quarter earnings conference call, in 2018, the company benefited from the robust performance of its key established brands such as Listerine, Neutrogena, Tylenol, Motrin, Aveeno, as well as new consumer brands like OGX. Additionally, the strong relaunch of Johnson’s Baby brand helped boost Consumer business revenues in fiscal 2018. Johnson & Johnson is focused on strengthening its position in the consumer business through the introduction of innovative products and its continued geographic expansion strategy.

The company is focused on achieving above-market growth rates for its Medical device business in fiscal 2020 through better implementation of the strategy and continued product innovation. In fiscal 2020, the company reported robust sales in key areas of its Medical device business such as Vision, Advanced Surgery, and Interventional Solutions.

Recently launched products such as Erleada and Tremfya are expected to witness robust uptake in fiscal 2019. Additionally, established products such as Imbruvica, Stelara, and Darzalex are expected to report label expansion and increased uptake in fiscal 2019.

Potential regulatory approval and subsequent market launch of products such as esketamine in treatment-resistant depression indication and erdafitinib in the bladder cancer indication are also expected to prove to be a major growth driver for the company in fiscal 2019.

In the next article, we’ll discuss balance sheet and shareholder returns for Johnson & Johnson in greater detail.

Latest articles

German chip maker Infineon Technologies has reportedly raised 1.55 billion euros (~$1.74 billion) in capital by selling its shares to fund its acquisition of Cypress Semiconductor (CY). Infineon has sold ~113 million new shares at 13.70 euros each.

As of June 18, Dunkin’ Brands (DNKN) was trading at $80.07, an 8.9% rise since reporting its first-quarter earnings on May 2. Also, DNKN was trading at a premium of 29.8% from its 52-week low of $61.69 and a discount of 1.6% from its 52-week high of $81.40.

19 Jun

Are Lower Oil Prices Weighing on ExxonMobil Stock?

WRITTEN BY Maitali Ramkumar

ExxonMobil (XOM) stock has fallen 7.1% in the second quarter so far. Let's review ExxonMobil's stock performance in comparison to oil price changes and equity market movements in the quarter.

19 Jun

As Facebook Unveils Libra, MSFT and CRM Join a Blockchain Group

WRITTEN BY Mayur Sontakke, CFA, FRM

On June 18, Facebook (FB) launched Libra, its own cryptocurrency. On the same day, CoinDesk published another piece of blockchain news that didn’t receive as much fanfare as Facebook’s Libra news. Was the timing a coincidence? We think not.

Uber Technologies (UBER) has picked Melbourne as another test site for its flying taxi service known as UberAir. The Australian city is the first international test site Uber has chosen for its flying taxi service. The addition of Melbourne brings the number of test locations Uber has picked for its UberAir service to three.

Lyft (LYFT) and Uber Technologies (UBER) are pushing back against California legislation that would require them to recognize their drivers as employees rather than independent contractors. The legislation would require companies like Lyft to give their drivers the compensation and benefits spelled out under California’s employment regulations.

172.31.16.229